ARTICLE | Company News

Repligen sues ImClone

May 6, 2004 7:00 AM UTC

RGEN and the Massachusetts Institute of Technology filed suit against ImClone alleging that the manufacture of IMCL's Erbitux colorectal cancer drug infringes a university patent that is exclusively licensed to RGEN. The patent expired on May 5, but RGEN and MIT have filed for a patent term extension. ...